

Questions and answers 14.6.2021

1. How is going with Chinese business and screenings etc.?

We do not currently have any ongoing screening for GastroPanel.

2. Biohit's patents are about to expire, how will this affect the company (especially in China)?

Patents have their own lifespan, and in our view, this is not relevant in China for the company's royalty claims.

3. Why has your information been weak and big things for the investor, for example, about China, has only been found in Helsingin Sanomat magazine?

Biohit does not inform Chinese matters on their behalf.

4. How can Liu Feng, CEO of Hefei, continue on Biohit's Board of Directors when Biohit Corporation initiates arbitration proceedings with Hefei for breach of the license agreement?

Contract negotiations are underway with the aim of avoiding arbitration.

5. Can you open up more on the impact on Biohit of the arbitration proceedings for breach of the Hefei license agreement that you have initiated? Your own view, for example, on the duration of the case and the impact on Biohit, etc.?

We will inform you at the end of the contract negotiations.

6. What is the market and competitive situation for Gastropanel in China?

As GastroPanel reliably finds *Helicobacter pylori* and the resulting atrophic gastritis with its stomach cancer and other risks and there is no vaccine for *Helicobacter pylori* or atrophic gastritis, we believe that the entry of competitors will increase GastroPanel's awareness, overall demand and expanding deployment.

7. How does the expiry of a method patent at the year stage affect the situation?

Patents have their own life cycle and, in our view, despite their expiration, sales of our products are growing.

8. Do unpaid royalties apply to Gastropanel or Hefei corona tests?

Applies to GastroPanel.

9. What is the company's relationship with Liu Feng? When is the dispute expected to be resolved?

Solution-focused contract negotiations are underway.

10. Why has the Strategy and Vision section of the Annual Report been removed as Objective 1 to increase revenue in China?

The strategy and vision are the same as earlier.

11. Has a partner been found in China for the research and marketing of Acetium?

Partner GrandPharma has been announced before. Possible further collaborations in research and marketing are being discussed.

12. What does the Shubang market look like? How much return is it realistic to expect over the next 2 years?

Shubang's marketing continues, the company's product return expectations are not announced separately.

13. How is Melon OOO's factory project progressing?

The project is progressing according to the agreements.

14. What kind of return is realistic to expect from Russia over the next 2 years?

We do not comment on return expectations for individual regions.

15. Why did Korpela get fired?

The company is looking for a CEO who is strongly involved in international marketing.

16. Why did Kainulainen leave the company?

This is Kainulainen's personal matter.

17. How is it possible that the Gastropanel rapid test has been delayed for so many years? When will the CE mark finally be obtained and what will be the market impact?

The pandemic delayed all of the company's projects. Other issues will be announced later.

18. What percentage of revenue growth does the company forecast for this year?

We do not provide a forecast of percentage growth. According to current guidelines, we expect significant growth.

19. How does the company expect its turnover to develop in the coming years?

Given the need for our company's products, we have a positive view of the future.